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OBJECTIVES: To evaluate the clinical outcomes and identify the predictors of mortality in elderly patients
undergoing peritoneal dialysis.
METHODS: We conducted a retrospective study including all incident peritoneal dialysis cases in patients X65
years of age treated from 2001 to 2014. Demographic and clinical data on the initiation of peritoneal dialysis
and the clinical events during the study period were collected. Infectious complications were recorded. Overall
and technique survival rates were analyzed.
RESULTS: Fifty-eight patients who began peritoneal dialysis during the study period were considered for
analysis, and 50 of these patients were included in the final analysis. Peritoneal dialysis exchanges were
performed by another person for 65% of the patients, whereas 79.9% of patients preferred to perform the
peritoneal dialysis themselves. Peritonitis and catheter exit site/tunnel infection incidences were 20.4±16.3 and
24.6±17.4 patient-months, respectively. During the follow-up period, 40 patients were withdrawn from
peritoneal dialysis. Causes of death included peritonitis and/or sepsis (50%) and cardiovascular events (30%).
The mean patient survival time was 38.9±4.3 months, and the survival rates were 78.8%, 66.8%, 50.9% and
19.5% at 1, 2, 3 and 4 years after peritoneal dialysis initiation, respectively. Advanced age, the presence of
additional diseases, increased episodes of peritonitis, the use of continuous ambulatory peritoneal dialysis, and
low albumin levels and daily urine volumes (o100 ml) at the initiation of peritoneal dialysis were predictors of
mortality. The mean technique survival duration was 61.7±5.2 months. The technique survival rates were
97.9%, 90.6%, 81.5% and 71% at 1, 2, 3 and 4 years, respectively. None of the factors analyzed were predictors
of technique survival.
CONCLUSIONS: Mortality was higher in elderly patients. Factors affecting mortality in elderly patients included
advanced age, the presence of comorbid diseases, increased episodes of peritonitis, use of continuous
ambulatory peritoneal dialysis, and low albumin levels and daily urine volumes (o100 ml) at the initiation of
peritoneal dialysis.
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’ INTRODUCTION
The total number of elderly patients initiating dialysis
regimens is expected to increase due to rising life expectan-
cies around the world. Data from the US Renal Data System
(USRDS) indicate that the number of patients older than 80
who initiated dialysis increased from 7,054 in 1996 to 13,577
in 2003 (1). In France, peritoneal dialysis (PD) is commonly
used among elderly patients, and more than one-half of all
PD patients are 470 years old. In Hong Kong, 80% of all
dialysis patients are on PD, and the median age of these
patients is 62 years (2). In Canada, the majority of patients
starting dialysis are older than 65 years (3).
PD in elderly patients is increasingly important due to the
rapid growth of this population. PD has several advantages
and disadvantages in the elderly. Elderly patients have a
higher incidence of intestinal complications, including
diverticulosis, bowel perforations, and constipation. More-
over, many elderly patients have undergone previous
abdominal surgeries, which increases the risk of adhesionsDOI: 10.6061/clinics/2015(05)10
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and abdominal wall leaks. Older patients on dialysis also
often have multiple comorbidities, including diabetes melli-
tus, hypertension and cardiovascular and cerebrovascular
diseases (4). The under-utilization of PD in elderly patients is
linked to the inability of the patient to perform PD exchanges
due to functional impairments or cognitive dysfunction.
Older age may frequently be associated with contraindica-
tions for peritoneal dialysis (5). Therefore, dialysis decisions
in elderly patients must incorporate geriatric principles with
an emphasis on an accurate assessment of patient autonomy,
disabilities, and comorbidities (6).
There is no clear consensus concerning the optimal form of
renal replacement therapy for elderly patients. Furthermore,
little is known regarding the results of PD therapy in elderly
patients. Thus, the aim of this study is to provide information
regarding the clinical outcomes and survival rates of elderly
patients treated with PD.
’ MATERIALS AND METHODS
Records of 58 elderly patients (465 years and older) in our
PD unit who began PD therapy between June 2001 and
January 2014 due to end-stage renal disease (ESRD) were
evaluated retrospectively. Eight patients were excluded from
the study because their PD history was less than 90 days. The
data from the remaining 50 patients were collected and
evaluated. Neither open-label research nor questionnaires
were used in our study. Moreover, ethical committee
approval was not sought because of the retrospective nature
of the study.
Age, gender, educational level, socio-demographic char-
acteristics, the availability of someone to administer PD (e.g.,
themselves, their children or other persons, such as
healthcare workers), and the nature of the use of PD (patient
preference or a compulsory choice) were investigated
in-depth using patient records. We noted whether the patient
had previously received hemodialysis, and if so, the history
of the hemodialysis treatment was recorded. The etiology of
the ESRD and the presence of comorbid systemic diseases,
such as hypertension, cardiovascular disease (CVD), cere-
brovascular events, and malignancy, were recorded.
Systolic and diastolic blood pressure measurements, daily
urine volumes, daily mean ultrafiltration (UF) amounts, and
cardiothoracic indices were recorded for all patients at the
beginning and at the end of the study.
Serum urea, creatinine, calcium, phosphorus, albumin,
intact parathyroid hormone (iPTH), hemoglobin, transferrin
saturation and ferritin values were recorded at the beginning
of the PD treatment and at the final monitoring appointment.
Initiation of PD for continuous ambulatory peritoneal
dialysis (CAPD) refers to the time when the patient started
to use the PD solutions effectively, which generally refers to
performing 2-liter exchanges 4 times per day. Initiation of PD
for automated peritoneal dialysis (APD) refers to when the
patient started PD at the necessary exchange volumes, which
typically takes approximately 2–3 weeks after PD catheter
insertion to occur.
Incidences of infectious complications, including peritoni-
tis and exit site/tunnel infections, were determined. Factors
associated with mortality as well as patient and technique
survival rates were analyzed. Technique failure was defined
as the requirement for patient transfer to HD due to
peritonitis, inadequate ultrafiltration, exit site and/or tunnel
infections, or mechanical problems.
Statistical analyses were performed using the Statistical
Package for the Social Sciences software (version 11.0; SPSS
Inc., Chicago, IL, USA). w2 tests were used to assess
nonparametric variables. Independent sample t-tests were
used to analyze clinical and biochemical parameters. Patient
survival rates and technique survival rates were calculated
using Kaplan-Meier analysis. Risk factors and calculated
hazard ratios (HRs) for patient mortality and PD technique
failure were also analyzed using backward logistic regres-
sion models based on the Cox proportional hazards method.
Differences were considered statistically significant if the
p-value was less than 0.05.
’ RESULTS
Of the 367 patients who began PD during the study
period, 58 met our inclusion criteria. Eight patients with a PD
history of less than 90 days were excluded from our analysis.
The mean age of the remaining 50 patients (including
31 females) at the time of the initiation of PD was 71.8±4.9
years. The mean PD duration was 26.5±20.2 months. The
patient demographic data are presented in Table 1.
A total of 64% (n=32) of the patients performed PD with
the help of another person, including their child, their spouse
or another person, such as a healthcare worker. Fifty-eight
percent of patients (n=29) made a compulsory choice to
begin PD due to vascular access or social problems. Histories
of HD use were present in 24% of the patients, and the mean
period of HD therapy prior to PD was 62.3±43.9 (3–144)
months.
Etiologies of renal failure included diabetic nephro-
pathy (56%), chronic glomerulonephritis (18%), polycystic
kidney disease (8%), chronic pyelonephritis (8%), amyloi-
dosis (2%) and unknown causes (8%). In addition to
diabetes, comorbid diseases included hypertension (12%),
cerebrovascular accidents (10%), coronary artery disease
(7%), chronic obstructive pulmonary disease (8%), malig-
nancies (4%) and visual defects due to diabetic retino-
pathy (10%).
Table 1 - Demographic data of patients.
Variable Value
Age (years) 71.8±4.9
Gender (male/female) 19/31
Peritoneal dialysis duration (months) 26.5±20.2
Nature of PD decision (self/compulsory choice) 21/29
HD history (n), duration (months) (12) 62.3±43.9
Peritonitis incidence (patient-months) 20.4±16.3
Catheter exit site/tunnel infection incidence
(patient-months)
24.6±17.4
Comorbid diseases
Hypertension 12%
Cerebrovascular accident 10%
Coronary artery disease 7%
Chronic obstructive pulmonary disease 8%
Visual defects due to diabetic retinopathy 10%
Malignancy 4%
Etiology of renal failure
Diabetic nephropathy (n:28) 56%
Chronic glomerulonephritis (n:9) 18%
Polycystic kidney disease (n:4) 8%
Chronic pyelonephritis (n:4) 8%
Amyloidosis (n:1) 2%
Unknown/other (n:4) 8%
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The clinical and laboratory data at the initiation of PD and
at the final visit are presented in Table 2. The incidence of
peritonitis was 20.4±16.3 patient-months; the incidence of
infections at the catheter exit site/tunnel was 24.6±17.4
patient-months.
The PD modality was CAPD in 74% of patients (n=37); 3 of
these patients eventually required a transfer to APD (n=16).
The mean following time of APD therapy was 19.8-12.9
months. When compared with patients treated with APD,
the hemodialysis duration was longer in patients receiving
CAPD treatment (p=0.024). In patients receiving CAPD
treatment, initial and final UF amounts were greater and
systolic blood pressures and urine volume levels were lower
than in patients treated with APD (p=0.014, o0.001, 0.008
and 0.023, respectively). In 80% of the APD group and 50%
of the CAPD group, the procedure was performed by
someone other than the patient (p=0.04). Factors that
similarly affected CAPD and APD patients (p40.05)
included age, gender, etiology, educational status, nature of
the PD decision, and incidences of peritonitis and catheter
exit site/tunnel infections.
During the follow-up period, only 10 patients continued to
receive PD treatments. None of the patients received kidney
transplants (Table 3), and 30 patients died. Of the patients
who died, 10 were treated with APD and 20 were treated
with CAPD. The mortality rate was higher in patients treated
with CAPD (po0.001). Most of these deaths were caused by
cardiovascular events (30%) and peritonitis and/or sepsis
(50%). The underlying causes of peritonitis and/or sepsis
were Gram-negative bacteria (Escherichia Coli, Enterobacter
and Pseudomonas species) in 6 patients, Klebsiella and
Acinetobacter species in 4 patients, and fungi in 1 patient.
The causative microorganisms could not be isolated in
4 patients. In total, 10 patients were transferred to HD
because of infectious complications associated with PD
(50%), PD insufficiency (30%), and malnutrition (20%).
Severe peritonitis with Gram-negative bacteria (Escherichia
coli, Enterobacter and Pseudomonas species) in 4 patients and
frequent peritonitis in 1 patient warranted mandatory
transfers to HD.
The mean survival time for all patients was 38.9±4.3
months based on the Kaplan-Meier analysis. The survival
rates were 78.8%, 66.8%, 50.9% and 19.5% at 1, 2, 3, and
4 years, respectively. No significant difference was observed
in the survival rates between the two PD groups (log rank:
0.609) (Figures 1A and 1B). Patient age, nature of the PD
decision (self vs. mandatory), administration form (self vs. by
someone else), HD history status, history of additional
systemic diseases, PD treatment modality (CAPD and APD),
pretreatment urine volume (4100 ml/day vs.o100 ml/day),
incidence of peritonitis and catheter exit site/tunnel infec-
tions, pretreatment serum albumin levels, systolic (SBP) and
diastolic (DBP) blood pressures, and UF volumes were
analyzed using Cox proportional hazard models and back-
ward stepwise likelihood ratios (LRs) to identify independent
risk factors for patient mortality. Predictors of increased
mortality included advanced age, the presence of additional
systemic diseases, increased episodes of peritonitis, CAPD
modality, and low serum albumin levels and daily urine
volumes (o100 ml) at the initiation of PD (Table 4).
The mean technique survival duration was 61.7±5.2 months
based on Kaplan-Meier analysis. The technique survival rates
were 97.9%, 90.6%, 81.5%, and 71% at 1, 2, 3, and 4 years,
respectively. Technique survival rates were similar between the
two PD modalities (log rank: 0.788) (Figures 2A and 2B).
Patient age, nature of the PD decision, administration form (self
vs. by someone else), HD history, history of additional systemic
diseases, pretreatment urine volume, incidence of peritonitis
and catheter exit site/tunnel infections, PD treatment modality
(CAPD and APD), pretreatment serum albumin levels, SBP,
DBP, and UF volumes were analyzed using Cox proportional
hazard models and backward stepwise LRs to identify
independent risk factors affecting the technique survival rates.
None of the factors, including PD modality, were significant
predictors of technique survival.
’ DISCUSSION
In this study, advanced age, presence of comorbid systemic
diseases, increased episodes of peritonitis, CAPD modality, low
serum albumin levels and low daily urine volumes at the
initiation of PD were poor predictors of patient survival in
elderly PD patients. Infectious complications and cardiovascu-
lar events were the main causes of death, whereas the most
significant factor in warranting patient transfer to HD was the
presence of peritonitis and/or sepsis.
Dialysis for older patients with ESRD is a significant
challenge for healthcare providers. These individuals are
often referred to nephrologists during the later stages of the
disease. Moreover, these patients tend to have more
comorbidities such as cardiovascular diseases, malnutrition,
and hearing and visual impairments (7,8). All of these factors
are problematic for any dialysis modality. The prevalence of
elderly patients requiring renal replacement therapy has also
been increasing in recent years. Genestier et al. reported that
15% of the PD population was elderly and projected that this
proportion would increase to 40–41% in the future (9). The
elderly PD population in our study accounted for 15.8% of all
PD patients at our facility.
Table 2 - Clinical and laboratory data at the initiation of PD and
the final visit.
Parameters At the beginning of PD Final visit
Creatinine (mg/dl) 7.3±2.9 6.2±2.4
Albumin (g/dl) 3.5±0.5 3.6±0.7
Calcium (mg/dl) 9.1±0.8 9.2±0.9
Phosphorus (mg/dl) 4.5±1.7 3.9±1.5
Parathormone (pg/ml) 255±358 290±380
Hemoglobin (g/dl) 10.7±1.7 11.8±2.0
Cardiothoracic index (%) 50±0.5 49±0.5
Systolic blood pressure (mmHg) 115±26 102±28
Diastolic blood pressure (mmHg) 70±14 62±13
Ultrafiltration (ml/day) 988±511 982±457
Urine volume (ml/day) 562±425 502±390
Table 3 - Final status of the patients.
Cause %
Death (n:30)
Sepsis/peritonitis (n:15) 50
Cardiovascular events (n:9) 30
Malnutrition/PD insufficiency (n:3) 10
Unknown (n:3) 10
Transfer to hemodialysis (n:10)
Sepsis/peritonitis (n:5) 50
PD insufficiency (n:3) 30
Malnutrition (n:2) 20
Continued PD treatment (n:10)
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As the proportion of the older population increases, the
number of older PD patients will also increase. Mortality rates
in elderly PD patients are not favorable. In our study, the mean
survival time was 38.9 months, and the mean survival rates
were 78.8%, 66.8%, and 50.9% at 1, 2, and 3 years, respectively.
Mortality rates in the present study were higher than observed
in a previous study of ours that evaluated all of our PD patients
between 2001 and 2010 (10). Different results are observed in
other centers and other countries. One of the reasons for some
of the discrepancies in the reports is the lack of a standard
definition of ‘‘elderly patient.’’ Some authors, including us,
consider patients over 65 years of age as elderly, but
heterogeneity regarding this definition exists between studies.
Elderly patients on PD can attain favorable outcomes: the
2- and 5-year survival rates of patients over 65 years of age in
Hong Kong were reported to be 88% and 56%, respectively (11).
A study evaluating patients over 80 years of age reported a 12-
month survival rate of 83% and a 24-month survival rate of
41%. These numbers are higher than those of other similar
studies, which is most likely due to the presence of fewer
comorbid conditions in the patients included in their study.
Most reports of dialysis outcomes in elderly patients are
retrospective and use varying definitions of elderly. The
North Thames Dialysis Study (13) was a large prospective
study that defined elderly as 70 years of age or older when
starting dialysis. In this study, survival was assessed in
125 patients (age 70–86 years), and the overall 1-year
survival rate was 71%. De Vecchi et al. (14) compared the
outcomes of 63 consecutive non-diabetic patients older than
70 years who were treated with CAPD with the outcomes of
86 non-diabetic patients aged 40–60 years who were treated
over the same period. The 2-year patient survival rate was,
not surprisingly, lower in the older group (68% vs. 82%,
p o 0.001). Kadambi et al. (15) compared the outcomes
of three groups of patients of different ages (o50 years,
50–64 years, and 465 years); over 90% of the patients were
receiving APD. This was a large retrospective study
of 493 patients, 192 of whom were older than 65 years.
The authors found that patients over 65 years of age had a
higher mortality rate than the group of younger patients.
The reasons underlying the different survival rates may be
multifactorial in elderly patients. Recent data indicate that age
and the presence of comorbid conditions play a significant role
in dialysis mortality (16–20). Demographic characteristics of
patients (age, presence of diabetes, number of comorbid
diseases, presence of malnutrition, low residual renal function,
presence of hemodialysis history) were generally different in all
of these study populations (16,21–23). In the Cox proportional
hazard model used in our study, advanced age, the presence of
comorbid systemic diseases, increased episodes of peritonitis,
CAPD modality, and low serum albumin levels and low daily
urine volumes at the initiation of PD were predictors of poor
patient survival. Weinhandle et al. also observed increased
survival of PD in patients less than 65 years of age without
comorbid conditions (20). Kurella et al. observed a decreasing
mean survival rate after dialysis initiation in the older dialysis
population, with a result of 24.9 months in patients aged 65
to 79 years, 15.6 months in patients aged 80 to 84 years,
11.6 months in patients aged 85 to 89 years and 8.4 months in
patients aged 90 years and older (1). The authors also showed
that the dialysis population had a substantially lower average
life expectancy of 48 to 89 months compared with the
age-matched general population (1).
Dialysis may not confer a survival benefit in elderly patients
with significant comorbidities. As expected, the survival of
Figure 1 - Total patient survival (1A) and patient survival according to PD modality (1B).
Table 4 - Multivariate Cox proportional hazards model for
patient survival
RR 95% Cl p-value
Age 0.748 0.595–0.940 0.013
Presence of comorbid disease 8.326 3.34–18.416 0.02
Incidence of peritonitis 0.238 0.085–0.664 0.006
Pretreatment low serum albumin 0.170 0.042–0.831 0.025
Pretreatment urine volume 1.004 1.001–1.008 0.021
PD modality (CAPD) 2.861 1.281–17.879 0.018
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patients receiving PD was affected by comorbidities. In
addition, comorbidities were associated with the mortality risk
of patients receiving PD in an age-independent manner (24,25).
A study conducted in London by Murtagh et al. also
demonstrated a survival benefit for dialysis treatment in the
elderly (475 years) (26). However, in patients with ischemic
heart disease or significant comorbidities (score=2 in the
comorbidity scoring system by Davies et al.) (27), no survival
benefit was observed for dialysis treatment. In our study, we
found that the presence of comorbid conditions negatively
affected patient survival.
Malnutrition is common in ESRD patients and is a powerful
predictor of morbidity and mortality. In general, elderly
patients on any type of dialysis have poor nutritional status.
Studies comparing nutritional statuses of PD and HD patients
are scant, but there is no clear evidence that nutritional status is
worse in elderly PD patients despite the potential for protein
loss in the effluent (28). PD patients may be severely
hypoalbuminemic at the initiation of dialysis (29) and may
remain at higher risk of malnutrition due to constant protein
loss in the effluent. Moreover, malnutrition may be significantly
higher among high peritoneal transporter patients and in
patients experiencing peritonitis. We suspect that this effect
accounts for the decreased survival rate in patients with lower
serum albumin levels at the initiation of PD.
Peritonitis is a major complication in patients receiving PD.
Peritonitis is the major cause of technique failure and represents
a significant cause of morbidity and mortality (30). The reported
rates of peritonitis in elderly patients have varied in the litera-
ture. Rates have been reported to be higher than, similar to, or
lower than the rates observed in younger patients (14,15,31–36).
Elderly patients could be more susceptible to peritonitis because
of functional impairments, immunodeficiency and diverticulitis.
Our results showed that the incidence of peritonitis was similar
to the ISPD Guidelines target (37). The higher peritonitis
incidence in our patients was probably due to the high rate of
administration of PD by someone other than the patient.
Cardiovascular disease is prevalent in CKD patients. In
fact, it is the most frequent cause of death in CKD patients,
accounting for approximately 50% of all deaths (38). A report
from a Far-Eastern country suggested that the most
significant causes of death in CKD patients were infections
(61%) and cardiovascular events (39%) (39). These data
correlate well with our study, as we also found that the most
frequent causes of death were infections (peritonitis and/or
sepsis) and cardiovascular events.
Inter-study variability exists regarding the definition of
technique failure. Many studies, including the present study,
define technique failure as a requirement for transfer to HD
(40,41). However, some authors define technique failure as
death or a requirement for transfer to HD (42). In addition to
the differences between definitions, technique survival rates
may differ between countries or even between clinics in the
same country (39,40,43). The most common causes of
transfers from PD to HD were PD-related infections and
inadequate dialysis (39). Similarly, infections (peritonitis
and/or sepsis) and inadequate dialysis were the most
important causes of technique failure in our study. The
mean technique survival duration was 61.7±5.2 months,
and the technique survival rates were 97.9%, 90.6%, 81.5%
and 71% at 1, 2, 3 and 4 years, respectively. These data are
consistent with similar studies from the literature (14). We
could not find any significant risk factors with effects on
technique survival, which was probably because of the small
size of the study population that was transferred to HD.
In conclusion, although different survival rates in PD patients
have been reported in different studies, mortality was high in
elderly PD patients in our study. The factors affecting mortality
and survival rates in our elderly patients are advanced age, the
presence of comorbid systemic diseases, increased episodes of
peritonitis, and low serum albumin levels and diastolic blood
pressures at initiation of PD. Transfers to HD and death were
the most common causes of withdrawal from PD. Infectious
complications and cardiovascular events were the main causes
Figure 2 - Technique survival for all patients (2A) and technique survival by PD modality (2B).
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of death, whereas peritonitis and/or sepsis and inadequate
dialysis were the most prevalent reasons for transferring to HD.
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